News Release: Bolar Pharmaceuticals Introduces Immmiflex And Hunza
Bolar Pharmaceuticals Ltd, a Nigerian pharmaceutical company involved in the marketing, sales and distributionof pharmaceuticals and healthcare products, today announced the planned introduction of two innovative and unique natural medicinal products into the Nigerian market. These products are Immiflex and Hunza.
Immiflex is a unique product which contains the ingredient Wellmune WGP, a patented beta-glucan which is a naturally occurring polysaccharide derived from cell wall of bakers yeast (Saccharomyces cerevisiae). We define the specific and proprietary form of yeast beta-glucan, as 1, 3/1, 6 beta glucan used in Bolar’s Immiflex product by the trade name Wellmune WGP®. It differs from other forms of beta-glucan in both chemical structure and biological activity. The ingredient Wellmune WGP is owned and patented by Biothera, an American biotechnology company.
Immiflex contains this Wellmune WGP that has a natural priming effect on the innate Immune system, the body’s first line of defense against infection and has been shown to be highly effective at optimizing immune function in studies. When we are born we have an active innate immune system and an inactive acquired immune system. The acquired immune system develops as we are exposed to various immune challenges and provides the specific “memory “of our immune system. However, the innate immune cells acts as our front line of defense to recognise and destroy the majority of intruders that can cause infection.
Immiflex is indicated to be used to strengthen and enhance the immune system, and can be used specifically in those wanting to reduce the incidence of coughs and colds, those who suffer malaria frequently, those wanting to offset the effects of stress, those who are immuno-suppressed, those who undertake a lot of exercise, those whose immune system are challenged in daily life, those who are HIV positive, and those suffering from cancer.
Hunza is a unique natural herbal supplement which contains Laetrile or Vitamin B17, Reishi and Vitamin C. The main active constituent Laetrile has been studied and used in cancer prevention and treatment for over 40 years. Reishi helps to boost the immune system, while Vitamin C acts as an antioxidant. Laetrile or Vitamin B17 is available from various food sources including Apricot seeds, Almond seed, Apple seeds, cassava, caribou and salmon berries.
Cancer is now regarded as a chronic metabolic disease, and in history, these – scurvy, rickets, pellagra, beriberi – have only ever been conquered by a change in nutrition. “We work on the premise that the human body becomes the sum total of what it absorbs,” says one former NHS (UK) doctor who now runs a clinic specialising in a nutritional approach to the treatment of metabolic disease. “Many of today’s serious disorders are caused primarily as a result of dysfunctional diet and the way the body processes what we put into it.” (“A chronic disease is one which usually does not pass away of its own accord. A metabolic disease is one which occurs within the body and is not transmittable to another person.”) [G. Edward Griffin World Without Cancer (American Media, California, 1974 and 1997) p56-57]
Hunza provides alternative therapy for the prevention and treatment of cancer. Hunza is a herbal agent containing Laetrile whose anti-tumour action was known empirically for many years, but in the last thirty five years has been scientifically proven, primarily through the clinical studies directed by well respected metabolic physicians around the world. Among them are Dr. Ernesto Contreras Rodriguez, of the Oasis of Hope Hospital (Formerly Centro Medico y Hospital Del Mar at Playas de Tijuana, B.C.N. Mexico); Dr. Ernst T. Krebs, Jr., who developed Laetrile; Dr. Philip E. Binzel, Jr., a physician in Washington Court House, Ohio, who has used Laetrile for over twenty years with outstanding success just to name a few; and many others from over twenty countries with equally impeccable credentials.
Bolar will support the medical profession and patients with extensive health education in the areas of immunity, cancer, and alternative therapies. We believe these two products will provide the medical profession with useful options for enhancing immune systems and disease prevention; as well as cancer prevention and treatment.
Bolar is a leading Nigerian pharmaceutical company established in 1984, but started operations in 1986, with a retail pharmacy. Over the years Bolar has represented several multinational companies in marketing and distribution. These include Johnson and Johnson, Astra Zeneca, Pharmacia and Upjohn, and Grunenthal. Bolar is presently focusing on developing own brands based on unique and natural ingredients and products, as well as new molecules which have been shown extensively to provide viable options for disease management and treatment.
Bolar has partnered with local and international organizations to gain access to these unique ingredients and molecules. Over the coming years, Bolar will be introducing products in chronic disease areas where present treatments are unsatisfactory or could be improved upon. These include sickle cell, hepatitis, diabetes, cancer, BHP (Benign Prostatic Hyperplasia), Cardiovascular disease (CVD) and arthritis.
These two products will be launched during two seminars that are being organized on the 13th and 15th of September, 2011.
For more Information, contact:
Corporate Affairs
BOLAR PHARMACEUTICALS LTD
01-7739108, 08034105614, 08034499670
